Mucosal injury associated with NCX 4016 is less than that of aspirin

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1406, 2003-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin

By Momi S.   Emerson M.   Paul W.   Leone M.   Mezzasoma A.M.   Del Soldato P.   Page C.P.   Gresele P.  

European Journal of Pharmacology, Vol. 397, Iss. 1, 2000-05 ,pp. : 177-185

Elsevier

Access to resources Recommend Favorite

Nitric oxide-donating aspirin (NCX 4016): an overview of its pharmacological properties and clinical perspectives

By Bolla Manlio   Momi Stefania   Gresele Paolo   Soldato Piero  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 1, 2006-02 ,pp. : 145-154

Springer Publishing Company

Access to resources Recommend Favorite

NCX 4016: gastric damage-sparing inhibition of COX activity

By  

Inpharma, Vol. 1, Iss. 1454, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Aspirin use less than optimal in stroke survivors in the USA

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 647, 2012-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Aspirin may offer less survival benefit in patients with diabetes after acute coronary syndromes than in those without diabetes

By  

Inpharma, Vol. 1, Iss. 1629, 2008-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite